During the transition phase, around 20% of individuals with PWS displayed a GHD status based on BMI-dependent criteria (114), while GHD was found in 8-38% of adult patients (115)
For weight management, Wegovy (semaglutide 2.4 mg) is the FDA-approved option, typically prescribed for patients with a BMI of 30 or higher, or 27+ with a weight-related condition
When combined with a balanced diet and exercise, it can reduce some pounds
These receptors might also themselves be potential targets for treatment approaches aiming to enhance GLP-1 secretion
GLP-1 Agonists FDA-Approved for Type 2 Diabetes Semaglutide (Ozempic) Approved December 5, 2017, Ozempic represents a once weekly subcutaneous injection that revolutionized diabetes care
[1] GLP-1 agonists: the next big disruptor in society [2] Obesity Profile: short statistical commentary May 2024 GOV.UK